Insights in Cardiovascular and Hematologic Drugs: 2022

29.6K

views

26

authors

6

articles

Editors

1

Michigan State University

Impact

Mechanisms of selected novel therapies in the treatment of pulmonary arterial hypertension. Green arrows indicate pathway stimulation; red arrows indicate inhibition. Some pathways have been simplified for the purposes of depiction within the diagram. AM, adrenomedullin receptor; ASK1, apoptosis signal-regulating kinase 1; BET, bromodomain and extaterminal domain; BMPR2, bone morphogenetic protein receptor 2; CGRP, calcitonin gene-related peptide; mTOR, mammalian target of rapamycin; NF-κB, nuclear factor kappa light chain enhancer of activated B cells; Nrf2, nuclear factor erythroid 2-related factor 2; PARP, poly (ADP-ribose) polymerase; PDH, pyruvate dehydrogenase; PDGFR, platelet-derived growth factor receptor; PDK, pyruvate dehydrogenase kinase; PPAR-γ, peroxisome proliferator activated receptor gamma; ROCK, Rho-associated protein kinase; RXFP1, relaxin family peptide receptor 1; TPH1, tryptophan hydroxylase 1; VPAC, vasoactive intestinal polypeptide receptor.

Review

15 December 2022

Novel and emerging therapies in pulmonary arterial hypertension

Steven J. Cassady

, 1 more and

Gautam V. Ramani

9,461 views

8 citations

UCSC Genome Browser view of genomic region for PIM1 variants. (A) UCSC Genome Browser for all three variants. Green vertical line depicts location of variant, labeled on top. Dark blue regions indicate the 6 exons for PIM1 plus untranslated regions (5′ and 3′ UTRs are narrower dark blue sections). Black region of “Txn Factor ChIP” indicates density of transcription factor ChIP-seq clusters from ENCODE. Black graphic for “Heart DS” indicates the Dnase I hypersensitivity density signal from ENCODE/Duke. Bottom five tracks indicate the predicted chromatin state from Roadmap. Red indicates a transcription start site region for five tissues, HRT.ATR.R (Right Atrium), HTR.VENT.L (Left Ventricle), HRT.VNT.R (Right Ventricle), VAS.AOR (Aorta), LNG (Lung). (B) UCSC Genome Browser focused on exonic variant rs192449585 and PIM1 gene.

Original Research

08 February 2023

Identification of novel genetic variants, including PIM1 and LINC01491, with ICD-10 based diagnosis of pulmonary arterial hypertension in the UK Biobank cohort

Alex Pu

, 3 more and

Charles C. Hong

3,614 views

6 citations

Article Cover Image

Mini Review

03 November 2022

Oxidized phospholipids are biomarkers, drug targets, and drug leads

Olga V. Oskolkova

, 2 more and

Valery N. Bochkov

Enzymatic oxidation or autooxidation of esterified polyunsaturated fatty acids (PUFA) residues within phospholipids in cell membranes or circulating lipoprotein particles leads to the formation of a broad range of oxidized phospholipid (OxPL) species. Chronically elevated OxPL levels present in circulation and atherosclerotic plaques are thought to induce proinflammatory and injurious effects on blood- and vessel wall cells. However, analysis of the structure-activity relationship also identified specific OxPL products exhibiting prominent anti-inflammatory, pro-survival and barrier protective properties. This minireview will briefly summarize rapidly accumulating evidence pointing to the importance of OxPLs in pathology, where they can play multiple roles of biomarkers, drug targets and drug leads.

2,988 views

7 citations

Correlations between plasma concentrations of NT-proBNP and plasma neuronal markers NfL (A,B) and total Tau (A,C) in total heart failure cohort (A) or separately in HFrEF (red symbols and lines) and HFpEF (blue symbols and lines) cohorts (B,C). All concentrations in pg/mL are log transformed before analysis of correlation. r, correlation coefficient; NT-proBNP, N-terminal pro-brain natriuretic peptide; NfL, Neurofilament light chain protein.

Original Research

18 October 2022

Plasma brain injury markers are associated with volume status but not muscle health in heart failure patients

Shouri Lahiri

, 9 more and

Ting Ting Hong

1,471 views

1 citations

Key Areas for Cardiovascular Drug Discovery Within the Context of Academia-Biotech-Pharma Ecosystem. Successful cardiovascular drug discovery effort will rely on continual progress in academia in basic (hexagons) and translational (rounded squares) research areas to gain deeper mechanistic insights to human heart disease. Moreover, within the academia-biotech-pharma ecosystem, these research areas must cross-fertilize across disciplines to accelerate drug discovery. While much of the fundamental discoveries originate in academia, biotech (BT) milieu facilitates the translation of ideas into products through de-risking in the early stages. By providing seed funding, industry know-how and resources, large pharmaceutical companies can serve as anchor institutions that catalyze innovative ideas into new therapies. Finally, academic institutions play an essential role of training future drug makers.

Specialty Grand Challenge

23 September 2022

The grand challenge of discovering new cardiovascular drugs

Charles C. Hong

6,459 views

6 citations

Article Cover Image

Mini Review

12 October 2022

Current and potential therapeutic strategies for transthyretin cardiac amyloidosis

Marcus A. C. Williams

, 2 more and

Mark J. Ranek

5,206 views

4 citations

Open for submission

Frontiers in Drug Discovery

Human iPSC Modeling of Heart Disease for Drug Screening

Edited by Alvaro Macias, Luca Sala

Deadline

31 July 2025

Recommended Research Topics

Frontiers in Drug Discovery

Drug Discovery and Development Explained: Introductory Notes for the General Public

Edited by Bruno Villoutreix, Jean-Luc Poyet, Katya Tsaioun

220.6K

views

46

authors

11

articles

About

We are now entering the third decade of the 21st Century, and, especially in the last years, the achievements made by scientists have been exceptional, leading to major advancements in the fast-growing field of Drug Discovery.

Frontiers has organized a series of Research Topics to highlight the latest advancements in research across the field of Drug Discovery, with articles from the members of our accomplished Editorial Boards. This editorial initiative of particular relevance, led by Prof. Hong, Specialty Chief Editor of the Cardiovascular and Hematologic Drugs section, is focused on new insights, novel developments, current challenges, latest discoveries, recent advances, and future perspectives in the field of Cardiovascular and Hematologic Drugs.

The Research Topic solicits brief, forward-looking contributions from the editorial board members that describe the state of the art, outlining recent developments and major accomplishments that have been achieved and that need to occur to move the field forward. Authors are encouraged to identify the greatest challenges in the sub-disciplines, and how to address those challenges.

The goal of this special edition Research Topic is to shed light on the progress made in the past decade in the Cardiovascular and Hematologic Drugs field, and on its future challenges to provide a thorough overview of the field. This article collection will inspire, inform and provide direction and guidance to researchers in the field.

We are now entering the third decade of the 21st Century, and, especially in the last years, the achievements made by scientists have been exceptional, leading to major advancements in the fast-growing field of Drug Discovery.

Frontiers has organized a series of Research Topics to highlight the latest advancements in research across the field of Drug Discovery, with articles from the members of our accomplished Editorial Boards. This editorial initiative of particular relevance, led by Prof. Hong, Specialty Chief Editor of the Cardiovascular and Hematologic Drugs section, is focused on new insights, novel developments, current challenges, latest discoveries, recent advances, and future perspectives in the field of Cardiovascular and Hematologic Drugs.

The Research Topic solicits brief, forward-looking contributions from the editorial board members that describe the state of the art, outlining recent developments and major accomplishments that have been achieved and that need to occur to move the field forward. Authors are encouraged to identify the greatest challenges in the sub-disciplines, and how to address those challenges.

The goal of this special edition Research Topic is to shed light on the progress made in the past decade in the Cardiovascular and Hematologic Drugs field, and on its future challenges to provide a thorough overview of the field. This article collection will inspire, inform and provide direction and guidance to researchers in the field.

Share

Editors

Michigan State University

Impact

29,614 Total views

24,274 Article views

4,978 Article downloads

362 Topic views

Published In

Journal Thumbnail

Frontiers in Drug Discovery

Cardiovascular and Hematologic Drugs

About Frontiers Research Topics

With their unique mixes of varied contributions from Original Research to Review Articles, Research Topics unify the most influential researchers, the latest key findings and historical advances in a hot research area! Find out more on how to host your own Frontiers Research Topic or contribute to one as an author.

Suggest a topic